Objectives: A 2017 laboratory survey conducted by the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) asked participants which antimicrobials they would report for given organisms in either blood or urine cultures in order to identify opportunities for improvement of antimicrobial reporting.
Introduction
Antimicrobial use drives MDR, thereby limiting future treatment options. MDR organisms may be transmitted from person to person in the healthcare setting and in the community. Such resistance is widely recognized as a major threat to public health. 1 Antimicrobial use causes Clostridioides (Clostridium) difficile infection and emerging evidence suggests antimicrobial effects on the human microbiome that go beyond infectious consequences and may be long-lasting. 2 Antimicrobial stewardship (AMS) is considered a key strategy to prevent the emergence of antimicrobial resistance and the Microbiology laboratory has an important role in AMS.
Microbiology laboratory reporting practice 3, 4 and selective reporting of antimicrobials influence clinicians' prescribing practice and can be associated with changes in local antimicrobial resistance profiles in both hospital and primary care settings. [5] [6] [7] [8] [9] [10] [11] [12] [13] National and international guidelines advocate selective reporting as part of AMS practice. 2, 14, 15 A recent survey has shown that selective reporting is poorly implemented in Europe. 16 There are very little other published data regarding the practice of selective reporting. The objective of this audit was to describe the practice of antimicrobial reporting by Microbiology laboratories in Australia and New Zealand and to identify opportunities for improvement of antimicrobial reporting.
Methods
An electronic 10-question survey was sent in 2017 to all laboratories (n " 156) participating in the (14) 1 (0) 92 (15) 1 (1) 80 (14) Co-trimoxazole 28 (3) 41 (12) 21 (5) 16 (1) 27 (3) 41 (11) Ciprofloxacin 46 (11) 33 (5) 45 (13) 12 (0) a 46 (10) 35 (6) Amoxicillin/clavulanate 48 (10) 31 (6) 46 (10) 44 (6) 17 (3) 63 (13) Cefazolin 11 (1) 35 (0) 10 (1) 23 (0) 12 (1) 32 (0) Ceftriaxone 32 (9) 41 (3) a 48 (9) 1 (0) 31 (11) 42 (2) a Amikacin 53 (6)
Number in parentheses indicates New Zealand laboratories only. 
Definitions
Inappropriate reporting: reporting of antimicrobials not appropriate for the site of infection. For isolates in blood cultures we defined this as reporting of cefalexin, nitrofurantoin, trimethoprim or norfloxacin as these antimicrobials do not generally achieve sufficient blood levels to adequately treat bacteraemia.
18,19
Over-reporting: reporting of broad-spectrum antimicrobials on isolates susceptible to narrow-spectrum antimicrobials. We defined 'ideal' reporting for a fully susceptible E. coli in blood cultures as reporting of ampicillin/amoxicillin, cefazolin/ceftriaxone/cefuroxime, gentamicin and co-trimoxazole with additional reporting of amoxicillin/clavulanate or ampicillin/sulbactam if the blood culture isolate was K. pneumoniae. For a fully susceptible E. coli in urine we considered reporting of ampicillin/amoxicillin, cefalexin, gentamicin, nitrofurantoin and trimethoprim as ideal. Overreporting was defined as reporting any antibiotic not considered 'ideal'.
Results
A response was received from 94/156 (60%) of laboratories; 83% were from Australia and 17% from New Zealand. Table 1 summarizes responses to questions 1, 2 and 3.
For a fully susceptible E. coli in blood cultures, 65% (55/84) of laboratories over-reported, 15% (10/65) of laboratories that tested meropenem reported the result and 42% (33/79) that tested ciprofloxacin reported the result.
For a fully susceptible E. coli in urine, 63% (59/94) of laboratories over-reported, 21% (12/57) of laboratories that tested ciprofloxacin reported the result, 49% (44/90) testing amoxicillin/clavulanate reported the result, 43% testing co-trimoxazole reported the result and one laboratory reported meropenem.
Overall, 82% (77/94) of laboratories over-reported at least one antibiotic.
Overall, 12% (10/84) of laboratories that performed susceptibility testing on blood culture isolates reported an antimicrobial considered not appropriate for treatment of bacteraemia; all of these were Australian laboratories. For a K. pneumoniae in blood cultures, seven laboratories reported cefalexin, six reported trimethoprim, two reported nitrofurantoin and one reported norfloxacin.
Twenty-six (28%) laboratories used only CLSI, 21 (22%) used only EUCAST and 16 (17%) used only CDS for general susceptibility testing; the other 31 (33%) laboratories used a hybrid of these methods (Figure 1) .
Where relevant, 33% of laboratories (28/84) reported susceptibility results differently for hospital patients compared with primary care patients, 27% (22/81) reported susceptibility results differently for patients in different clinical units (e.g. Intensive Care, Burns, Haematology/Oncology) and 54% (51/94) reported antibiotics differently for paediatric patients.
Eight laboratories (9%) responded 'No' to question 9 (In general, does your laboratory use 'cascade reporting'?); however, none of these laboratories reported meropenem for any of the scenarios.
Discussion
Appropriate reporting of antimicrobials includes reporting that is relevant for the body site of infection, the age of the patient and pregnancy status. CLSI M100 Standards include suggested groupings of antimicrobials that should be considered for testing and reporting. These are divided into 'primary test and report', 'optional primary test, report selectively', 'supplemental, report selectively' and 'supplemental for urine only'. 18 However, there are currently few international or peer-reviewed guidelines to guide laboratories whose reporting is based on various combinations of organism resistance profiles. Available international laboratory guidelines for susceptibility testing do specify intrinsic resistance profiles that can facilitate reporting of these antimicrobials to prevent their unnecessary and ineffective use.
18, 19 Even fewer peer-reviewed RCPAQAP audit of antimicrobial reporting JAC laboratory guidelines specify which antibiotics should be reported or suppressed for children or pregnant women; a recent version of UK Standards for Microbiology Investigations has included a new statement to recommend that laboratories suppress reporting of tetracycline for children and pregnant women. 20 Our study has shown a wide variety of antimicrobial reporting practice in Australia and New Zealand although most laboratories practise some selective reporting. Few laboratories reported antimicrobials that achieve low blood levels for blood culture isolates; however, such inappropriate reporting has the potential to endanger patient safety and should therefore be a priority target for selective reporting recommendations.
Ideally, selective reporting should follow a 'cascade' pattern where more antimicrobials are reported for more resistant organisms. 2, 5 When comparing antimicrobials reported for E. coli and K. pneumoniae in blood cultures, our study has shown that not all laboratories have such an approach. Our definitions of over-reporting and inappropriate reporting were based on suggested reporting in recently published Australian AMS guidelines 2 and on draft RCPA guidelines for Selective Reporting, which are currently in an external consultation phase. These guidelines are influenced by published international documents [18] [19] [20] and focus on avoiding reporting of broad-spectrum antimicrobials such as fluoroquinolones and carbapenems and other antimicrobials strongly associated with C. difficile infection (e.g. amoxicillin/clavulanate).
Many factors influence the ability of a laboratory to practise selective reporting. A recent European survey identified several barriers to implementation, mainly lack of guidelines, poor system support, insufficient resources and lack of professionals' capability. 16 The definition of ideal reporting may also differ according to local pharmacy restrictions and, for example, whether the laboratory services a large paediatric or obstetric population. Perception of the importance of reporting to include options for patients with b-lactam allergy or impaired renal function may influence reporting practice. Studies that explore the variation in reporting and reasons for the variation are important because they can inform the development of much-needed guidelines.
The definition of ideal reporting may also vary according to the susceptibility method used as, for example, CLSI allows reporting of cefazolin for Enterobacteriaceae, whereas EUCAST does not. A limitation of our study is that since laboratories followed more than one susceptibility method we were not able to measure the impact of this on the variation in reporting. However, we note that the only other reported similar study showed comparable results in the context of presumably more uniform susceptibility testing (EUCAST). This study by Pulcini et al. 16 was a survey sent to 'national representatives' of 38 European countries and the results are a summary of a total of 36 respondents. The study found that selective reporting is poorly implemented in Europe and is applied with huge heterogeneity. In comparison, our study comprises many more respondents and is the first published study to measure within-country variation in reporting.
There is currently very little published research on the practice of antimicrobial reporting. We found that a significant proportion of laboratories report very broad-spectrum antimicrobials despite the isolate being fully susceptible to narrow-spectrum agents. The majority of laboratories (82%) either over-reported or inappropriately reported at least one antimicrobial. This survey identifies significant opportunities for improvement of selective reporting of antimicrobials.
